Adherence to antiretroviral therapy for the success of emerging interventions to prevent HIV transmission: A wake up call

Journal of AIDS and Clinical Research

Volumn 3, Issue SPL ISSUE4, 2012, Pages

  Nachega, Jean B ^a,b   Uthman, Olalekan A ^b   Mills, Edward J ^c   Quinn, Thomas C ^a,d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF OTTAWA   (Canada)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Adherence; ART; PMTCT; PreP; TasP

Indexed keywords

EID: 84879806768     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.S4-007     Document Type: Review

References (63)

1. UNAIDS World AIDS day report (2011) How to get to zero: faster, smarter, better. The Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
2. WHO Global HIV/AIDS response (2011) Epidemic update and health sector progress towards universal access. Progress report 2011, World Health Organization, Geneva, Switzerland.
3. Holmes KK, Levine R, Weaver M (2004) Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 82: 454-461.
4. Hughes J, Baeten J, Lingappa J, Magaret A, Wald A, et al. (2011) Determinants of Per-act Infectivity of HIV-1 in the Partners in Prevention Study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA.
5. UNAIDS (2009) Condoms and HIV prevention: Position statement by UNAIDS, UNFPA and WHO. Geneva, Switzerland.
6. Weller S, Davis K (2002) Condom effectiveness in reducing heterosexual HIV transmission. Cochrane database syst Rev CD003255.
7. Kwon JA, Iversen J, Maher L, Law MG, Wilson DP (2009) The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: a model-based analysis. J Acquir Immune Defic Syndr 51: 462-469.
8. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS medicine 2: e298.
9. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369: 643-656.
10. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369: 657-666.
11. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
12. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, et al. (2010) Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 5: e11068.
13. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, et al. (2010) Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 376: 532-539.
14. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146: 564-573.
15. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of internal medicine 133: 21-30.
16. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, et al. (2004) The impact of adherence on CD4 cell count responses among HIV-infected patients. J Acquir Immune Defic Syndr 35: 261-268.
17. Nachega JB, Hislop M, Dowdy DW, Lo M, Omer SB, et al. (2006) Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 43: 78-84.
18. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, et al. (2006) Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl. AIDS 20: 1117-1123.
19. Grosskurth H, Gray R, Hayes R, Mabey D, Wawer M (2000) Control of sexually transmitted diseases for HIV-1 prevention: understanding the implications of the Mwanza and Rakai trials. Lancet 355: 1981-1987.
20. Grosskurth H, Mosha F, Todd J, Mwijarubi E, Klokke A, Senkoro et al. (1995) Impact of improved treatment of sexually transmitted diseases on HIV infection in rural Tanzania: randomised controlled trial. Lancet 346: 530-536.
21. Wawer MJ, Sewankambo NK, Serwadda D, Quinn TC, Paxton LA, et al. (1999) Control of sexually transmitted diseases for AIDS prevention in Uganda: a randomised community trial. Rakai Project Study Group. Lancet 353: 525-535.
22. Celum C, Wald A, Hughes J, Sanchez J, Reid S, et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371: 2109-2119.
23. Grant RM, Hamer D, Hope T, Johnston R, Lange J, et al. (2008) Whither or wither microbicides? Science 321: 532-534.
24. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 359: 463-472.
25. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360: 971-977.
26. Gallo MF, Kilbourne-Brook M, Coffey PS (2012) A review of the effectiveness and acceptability of the female condom for dual protection. Sex health 9: 18-26.
27. Johnston MI, Fauci AS (2011) HIV vaccine development--improving on natural immunity. N Engl J Med 365: 873-875.
28. Nabel GJ, Kwong PD, Mascola JR (2011) Progress in the rational design of an AIDS vaccine. Philos Trans R Soc Lond B Biol Sci 366: 2759-2765.
29. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, et al. (2000) Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA 283: 1175-1182.
30. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, et al. (2008) Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS 22: 973-981.
31. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, et al. (2000) Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 342: 921-929.
32. Anglemyer A, Rutherford GW, Baggaley RC, Egger M, Siegfried N (2011) Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database Syst Rev CD009153.
33. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, et al. (2010) Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329: 1168-1174.
34. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010) Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 363: 2587-2599.
35. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, et al. (2012) Preexposure Prophylaxis for HIV Infection among African Women. N Engl J Med 367: 411-422.
36. MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women. Pittsburgh.
37. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, et al. (2012) Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med 367: 423-434.
38. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, et al. (2012) Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women. N Engl J Med 367: 399-410.
39. Haberer JE, Baeten J, Celum C, Tumwesigye E, Katabira E, et al. (2011) Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the partners PrEP study. 18th Conference on Retroviruses and Opportunistic Infections. Boston, Massachusetts.
40. Ware NC, Wyatt MA, Haberer JE, Baeten JM, Kintu A, et al. (2012) What's love got to do with it? Explaining adherence to oral antiretroviral pre-exposure prophylaxis for HIV-serodiscordant couples. J Acquir Immune Defic Syndr 59: 463-468.
41. van der Straten A, Van Damme L, Haberer JE, Bangsberg DR (2012) Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS 26: F13-19.
42. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, et al. (2010) Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375: 2092-2098.
43. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG (2009) Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373: 48-57.
44. Mills EJ, Nachega JB, Buchan I, Orbinski J, Attaran A, et al. (2006) Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 296: 679-690.
45. Hall HI, Hughes D, Dean HD, Mermin JH, Fenton KA, et al. (2011) HIV Infection-United States, 2005 and 2008. MMWR Surveill Summ 60: 87-89.
46. Rudd P, Byyny RL, Zachary V, LoVerde ME, Titus C, et al. (1989) The natural history of medication compliance in a drug trial: limitations of pill counts. Clin pharmacol Ther 46: 169-176.
47. Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. (2010) Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet 376: 1838-1845.
48. Pop-Eleches C, Thirumurthy H, Habyarimana JP, Zivin JG, Goldstein MP, et al. (2011) Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders. AIDS 25: 825-834.
49. Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, et al. (2009) A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol 28: 1-10.
50. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, et al. (2011) HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 56: S22-S32.
51. Petersen ML, Wang Y, van der Laan MJ, Guzman D, Riley E, Bangsberg DR (2007) Pillbox organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis 45: 908-915.
52. Uchino BN (2006) Social support and health: a review of physiological processes potentially underlying links to disease outcomes. J Behav Med 29: 377-387.
53. Nachega JB, Mugavero MJ, Zeier M, Vitoria M, Gallant JE (2011) Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. Patient Prefer Adherence 5: 357-367.
54. Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, et al. (2011) A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 8: e1000422.
55. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, et al. (2012) Guidelines for Improving Entry Into and Retention in Care and Antiretroviral Adherence for Persons With HIV: Evidence-Based Recommendations From an International Association of Physicians in AIDS Care Panel. Ann Intern Med 156: 817-833.
56. Volpp KG, Troxel AB, Pauly MV, Glick HA, Puig A, et al. (2009) A randomized, controlled trial of financial incentives for smoking cessation. N Engl J Med 360: 699-709.
57. Volpp KG, John LK, Troxel AB, Norton L, Fassbender J, et al. (2008) Financial incentive-based approaches for weight loss: a randomized trial. JAMA 300: 2631-2637.
58. Stitzer ML, Polk T, Bowles S, Kosten T (2010) Drug users' adherence to a 6-month vaccination protocol: effects of motivational incentives. Drug Alcohol Depend 107: 76-79.
59. Seal KH, Kral AH, Lorvick J, McNees A, Gee L, et al. (2003) A randomized controlled trial of monetary incentives vs. outreach to enhance adherence to the hepatitis B vaccine series among injection drug users. Drug Alcohol Depend 71: 127-131.
60. Malotte CK, Hollingshead JR, Larro M (2001) Incentives vs outreach workers for latent tuberculosis treatment in drug users. Am j prev med 20: 103-107.
61. Haug NA, Sorensen JL (2006) Contingency management interventions for HIV-related behaviors. Current HIV/AIDS Rep 3: 154-159.
62. Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry NM, et al. (2007) Improved adherence with contingency management. AIDS patient care and STDS 21: 30-40.
63. Baird SJ, Garfein RS, McIntosh CT, Ozler B (2012) Effect of a cash transfer programme for schooling on prevalence of HIV and herpes simplex type 2 in Malawi: a cluster randomised trial. Lancet 379: 1320-1329.